Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 0.83 |
| ▸ | ADORA1 | P30542 | 16/20 | 0.83 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.83 |
| ▸ | HTR2B | P41595 | 2/20 | 0.83 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | HTR3A | P46098 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14903074 | 0.92 | ADORA3 (0.83) | ADORA3ADORA1ADORA2AHTR2B | |
| SCHEMBL3740313 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL28525054 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29524384 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL958891 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL958888 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL13388428 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29390151 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29523882 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29366953 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | The united States of America,as represented by Secretary,Dept.,of Health and Human Services (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | NT5E, NT5C2, NT5C3B | ADORA3 6/4885ADORA1 9/4885ADORA2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.